0001140361-23-051485.txt : 20231106 0001140361-23-051485.hdr.sgml : 20231106 20231106060632 ACCESSION NUMBER: 0001140361-23-051485 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231106 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231106 DATE AS OF CHANGE: 20231106 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GYRE THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001124105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 562020050 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51173 FILM NUMBER: 231377994 BUSINESS ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 650-266-8674 MAIL ADDRESS: STREET 1: 12730 HIGH BLUFF DRIVE, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: CATALYST BIOSCIENCES, INC. DATE OF NAME CHANGE: 20150820 FORMER COMPANY: FORMER CONFORMED NAME: TARGACEPT INC DATE OF NAME CHANGE: 20000919 8-K 1 ny20009756x14_8k.htm FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): November 6, 2023

Gyre Therapeutics, Inc.
(Exact name of registrant as specified in its charter)

Delaware
000-51173
56-2020050
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
     
12730 High Bluff Drive
Suite 250
San Diego, CA
92130
(Address of principal executive offices)
(Zip Code)

Registrant’s telephone number, including area code: (650) 266-8674

N/A
(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
  
Trading Symbol(s)
  
Name of each exchange on which
registered
Common Stock
  
GYRE
  
The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On November 6, 2023, GNI Group Ltd., a company incorporated under the laws of Japan with limited liability (“GNI Japan”), which holds an indirect controlling interest of Gyre Therapeutics, Inc., a Delaware corporation (the “Company”), issued a press release announcing that GNI Japan has updated the consolidated earnings forecast for the full-year 2023.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. The exhibit furnished under Item 7.01 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act, regardless of any general incorporation language in such filing.

Forward Looking Statements

This report and the press release attached as an exhibit contain forward-looking statements that pertain to future operating performance and that are not historic facts. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of GNI Japan and/or the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits. The following exhibits are being furnished herewith:


Exhibit Number
  
Exhibit Title or Description
     
 
Press Release, dated November 6, 2023
     
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
GYRE THERAPEUTICS, INC.
   
Date: November 6, 2023
By:
/s/ Charles C. Wu, Ph.D.
 
Name:
Charles C. Wu, Ph.D.
 
Title:
Chief Executive Officer

EX-99.1 2 ny20009756x14_ex99-1.htm EXHIBIT 99.1
Exhibit 99.1


Nov 6, 2023

 
Company Name:
GNI Group Ltd.
 
Representative:
Director, Representative Executive Officer,
President and CEO
Ying Luo, PhD
   
(Security Code: 2160, TSE Growth)
 
Contact Person:
Chief Financial Officer
Toshiya Kitagawa
   
(TEL. 03-6214-3600)

GNI Group Updates Full Year 2023 Consolidated Earnings Forecast

GNI Group Ltd., (TSE Growth security code: 2160, “the Company” below) today announced that the Group has updated the consolidated earnings forecast for the full-year 2023, which was published on August 3, 2023, as follows.

1)
The differences between the forecast and the previous forecast for 2023

Consolidated earnings forecast for full-year 2023 (January 1, 2023 – December 31, 2023)

 
Revenue
Operating profit
Profit before tax
Profit for the year
Profit attributable to owners of the parent
Basic earnings per share
(JPY Million)
(JPY Million)
(JPY Million)
(JPY Million)
(JPY Million)
(JPY)
Previous Forecast (A)
25,273
5,991
4,143
2,174
1,703
35.86
Revised Forecast (B)
26,267
7,280
6,430
4,351
2,005
42.20
Difference (B-A)
994
1,289
2,287
2,177
302
-
Difference in ratio (%)
3.9%
21.5%
55.2%
100.1%
17.7%
-
(Reference) 2022 Actual
17,418
1,377
767
(868)
388
8.19

2)
Reasons for the differences

The first is that the sales revenue of ETUARY®, the main product of our consolidated subsidiary, Beijing Continent Pharmaceuticals Co., Ltd., has been exceeding the plan in the second half of the fiscal year as in the first half.

Second, as disclosed on June 15, 2023, our consolidated subsidiary Cullgen Inc. is generating monthly sales revenue that exceeds the previous forecast based on the strategic alliance agreement signed with Astellas Pharma Inc.

Third, the exchange rates previously used for earnings forecast (US$1 = ¥130.77 and RMB1 = ¥19.38) have been revised to US$1 = ¥138.24 and RMB1 = ¥19.62.

As a result of these factors, revenue and profit are expected to significantly exceed the full-year forecast announced on August 3, 2023, and we have now revised our full-year consolidated forecast.


This material contains statements concerning the current plans, expectations and strategies of GNI Group Ltd. (“the Company”). Any statements contained herein that pertain to future operating performance and that are not historic facts are forward-looking statements. Forward-looking statements may include, but are not limited to, words such as “believe,” “plan,” “strategy,” “expect,” “forecast,” “possibility” and similar words that describe future operating activities, business performance, events or conditions. Forward-looking statements, whether spoken or written, are based on judgments made by the management of the Company, based on information that is currently available to it. As such, these forward-looking statements are subject to various risks and uncertainties, and actual business results may vary substantially from the forecasts expressed or implied in forward-looking statements. Consequently, investors are cautioned not to place undue reliance on forward-looking statements.

The information contained in this material does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Any decision to invest in or acquire securities of the Company must be based wholly on the information contained in the preliminary offering circular issued or to be issued by the Company in connection with any such offer and not on the contents hereof.

 
 EX-101.SCH 3 gyre-20231106.xsd XBRL TAXONOMY EXTENSION SCHEMA 000100 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 gyre-20231106_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Amendment Flag Document Fiscal Year Focus Document Fiscal Period Focus Document Period End Date Entity Registrant Name Entity Central Index Key Entity File Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Emerging Growth Company Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name EX-101.PRE 5 gyre-20231106_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 logo_gni.jpg begin 644 logo_gni.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Document and Entity Information
Nov. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 06, 2023
Entity File Number 000-51173
Entity Registrant Name Gyre Therapeutics, Inc.
Entity Central Index Key 0001124105
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 56-2020050
Entity Address, Address Line One 12730 High Bluff Drive
Entity Address, Address Line Two Suite 250
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92130
City Area Code 650
Local Phone Number 266-8674
Title of 12(b) Security Common Stock
Trading Symbol GYRE
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
XML 8 ny20009756x14_8k_htm.xml IDEA: XBRL DOCUMENT 0001124105 2023-11-06 2023-11-06 false 0001124105 NASDAQ 8-K 2023-11-06 Gyre Therapeutics, Inc. DE 000-51173 56-2020050 12730 High Bluff Drive Suite 250 San Diego CA 92130 650 266-8674 false false false false Common Stock GYRE false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$" M% ,4 " #/,&9799!YDAD! #/ P $P @ &N$@ 6T-O F;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #X$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 000100 - Document - Document and Entity Information Sheet http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports gyre-20231106.xsd gyre-20231106_lab.xml gyre-20231106_pre.xml ny20009756x14_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "ny20009756x14_8k.htm": { "nsprefix": "gyre", "nsuri": "http://ir.catalystbiosciences.com/20231106", "dts": { "schema": { "local": [ "gyre-20231106.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2004/ref-2004-08-10.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "labelLink": { "local": [ "gyre-20231106_lab.xml" ] }, "presentationLink": { "local": [ "gyre-20231106_pre.xml" ] }, "inline": { "local": [ "ny20009756x14_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 29, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation", "longName": "000100 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c20231106to20231106", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ny20009756x14_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c20231106to20231106", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "ny20009756x14_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://ir.catalystbiosciences.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 16 0001140361-23-051485-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001140361-23-051485-xbrl.zip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end